Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.
The Australian Technical Advisory Group on Immunisation (ATAGI) has published advice on seasonal influenza vaccines for 2023. Annual vaccination is recommended for all people six months of age and over and is particularly important…
Read more
The Pharmaceutical Benefits Scheme (PBS) listing for ruxolitinib has been expanded. The listing now includes acute or chronic graft-versus-host disease (GvHD) in patients with an inadequate response to corticosteroids. Ruxolitinib is an inhibitor of…
Read more
The Therapeutic Goods Administration (TGA) has issued a Medicines Safety Update on the use of pregabalin during pregnancy. The pregnancy risk category for pregabalin has changed from Category B3 to Category D, and product…
Read more
Several new contraindications have been added to the product information for Paxlovid™ (nirmatrelvir/ritonavir). This medication is now contraindicated with the medications shown in Table 1. Table 1. New contraindications added to Paxlovid™ product information…
Read more
The National Immunisation Program (NIP) has updated the vaccination schedule for human papilloma virus (HPV). A single dose of Gardasil® 9 is now recommended for the routine vaccination of young people, with the free…
Read more
Opicapone was added to the Pharmaceutical Benefits Scheme (PBS) on 1 February 2023. Opicapone is indicated as adjunctive therapy to a levodopa-decarboxylase inhibitor combination in adults with Parkinson’s disease who experience end-of-dose motor fluctuations….
Read more
